US shortage of GSK’s restless legs syndrome treatment Horizant – PMLiVE

by admin on May 18, 2013

US shortage of GSK's restless legs syndrome treatment Horizant
PMLiVE
Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. In its notice, the US regulator said GSK is “experiencing a backorder situation”, leaving an

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: